ACADIA Pharmaceuticals Inc

2026-07-22 04:11:36

Acadia Pharmaceuticals announced that the FDA has granted Fast Track designation to remlifanserin, its investigational drug for hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). The company is currently evaluating remlifanserin in the RADIANT development program, with top-line phase II results expected between September and October 2026. Acadia's shares have decreased by 6% year-to-date, but its marketed drugs, Nuplazid and Daybue, are expected to contribute significantly to future growth.

2026-07-21 21:09:45

Acadia Pharmaceuticals has been granted Fast Track designation by the FDA for its investigational drug remlifanserin, which is being developed to treat psychosis in patients with Alzheimer's disease. This designation aims to expedite the development and review process for drugs addressing serious conditions with unmet medical needs. The move could accelerate the availability of a new treatment option for this specific patient population.

2026-07-21 16:10:59

Stifel increased its price target for Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) to $25.00 from $24.00, maintaining a Hold rating. The firm's analysis focused on remlifanserin, a drug in development for Alzheimer's disease psychosis and Lewy body dementia psychosis, acknowledging its high-risk, high-reward profile. This update follows recent positive developments for Acadia, including FDA Fast Track designation for remlifanserin and a positive European regulatory opinion for DAYBUE, leading other analysts to also raise their price targets.

2026-07-21 14:41:06

Acadia Pharmaceuticals announced that its investigational drug, remlifanserin, has received FDA Fast Track designation for treating hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). The company is currently evaluating remlifanserin in phase II and phase III studies, with top-line phase II results expected between September and October 2026. Acadia's growth is also supported by its marketed drugs, Nuplazid and Daybue, which are expected to generate significant sales by 2028.

2026-07-21 04:11:36

Stifel increased its price target for Acadia Pharmaceuticals to $25.00 from $24.00, maintaining a Hold rating, based on its analysis of remlifanserin for Alzheimer's disease psychosis and Lewy body dementia psychosis. The firm acknowledges the drug's high-risk, high-reward profile while noting its mechanism is safe but modestly effective as an antipsychotic. Despite the uncertainties, recent positive developments such as Fast Track designation for remlifanserin and European regulatory approval for DAYBUE (trofinetide) have led other firms like Canaccord, Mizuho, and H.C. Wainwright to raise their price targets and maintain Buy/Outperform ratings.

2026-07-21 00:11:30

Stifel has increased its price target for Acadia Pharmaceuticals (NASDAQ:ACAD) to $25.00 from $24.00, maintaining a Hold rating, based on the potential of its drug candidate remlifanserin. While Stifel sees remlifanserin as high risk and high reward due to a well-designed phase 2 study, other analysts like Canaccord, Mizuho, and H.C. Wainwright have also raised price targets and maintained Buy or Outperform ratings following recent positive regulatory developments for remlifanserin and DAYBUE. These developments include Fast Track designation for remlifanserin in the U.S. and a positive opinion for DAYBUE in Europe.